{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T02:55:24Z","timestamp":1771124124442,"version":"3.50.1"},"reference-count":57,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T00:00:00Z","timestamp":1119830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Caspofungin, a semisynthetic derivative of the pneumocandin B<jats:sub>0<\/jats:sub>, is the first licensed compound of a new class of antifungal agents, the echinocandins. It attacks the fungal cell by selective inhibition of the beta\u2010(1,3)\u2010<jats:sc>d<\/jats:sc>\u2010glucan synthase, which is not present in mammalian cells. <jats:italic>In vitro<\/jats:italic> studies have indicated a potent fungicidal effect on <jats:italic>Candida<\/jats:italic> species, and <jats:italic>in vivo<\/jats:italic> studies in immunocompromised animals with invasive candidiasis demonstrated a favourable outcome. In randomized clinical trials in patients with oropharyngeal\/oesophageal and invasive candidiasis, caspofungin was at least as effective as amphotericin B deoxycholate, yet showed a significantly superior safety profile. Of patients with invasive aspergillosis refractory to or intolerant of other antifungal agents, 45% showed a partial or complete response to caspofungin given as a salvage treatment. Also, it demonstrated comparable clinical efficacy but superior tolerability in the empirical antifungal therapy in neutropenic patients compared with liposomal amphothericin B. Caspofungin has an excellent tolerability and a low potential for drug interactions. Thus, caspofungin represents an interesting and clinically valuable new antifungal drug that broadens the available therapeutic armamentarium for the treatment of invasive fungal infections.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2005.01131.x","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T13:48:35Z","timestamp":1119880115000},"page":"227-234","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin"],"prefix":"10.1111","volume":"48","author":[{"given":"Georg","family":"Maschmeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,27]]},"reference":[{"key":"e_1_2_15_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_2_15_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.8.1545"},{"key":"e_1_2_15_4_2","first-page":"334","article-title":"MK\u20100991","volume":"1","author":"Groll AH","year":"2002","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"e_1_2_15_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363200-00008"},{"key":"e_1_2_15_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.13.1206"},{"key":"e_1_2_15_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161080-00007"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.269"},{"key":"e_1_2_15_9_2","first-page":"31","article-title":"New antifungal drug tragets: a vision for the future","volume":"64","author":"Kurtz MB.","year":"1998","journal-title":"ASM News"},{"key":"e_1_2_15_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_2_15_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(03)00117-3"},{"key":"e_1_2_15_12_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.41.2.331","article-title":"Pneumocandin L\u2010743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro","volume":"41","author":"Franzot SP","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_15_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1985"},{"key":"e_1_2_15_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5729-5731.2003"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_2_15_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1068-1071.2003"},{"key":"e_1_2_15_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.7.3142-3146.2004"},{"key":"e_1_2_15_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1937"},{"key":"e_1_2_15_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1775"},{"key":"e_1_2_15_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1850-1854.2000"},{"key":"e_1_2_15_21_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.42.1.151","article-title":"Treatment of histoplasmosis with MK\u2010991 (L\u2010743,872)","volume":"42","author":"Graybill JR","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_15_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200210010-00009"},{"key":"e_1_2_15_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh179"},{"key":"e_1_2_15_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/423381"},{"key":"e_1_2_15_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"},{"key":"e_1_2_15_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_2_15_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1382-1383.2004"},{"key":"e_1_2_15_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1197-1203.2004"},{"key":"e_1_2_15_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_2_15_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2310-2318.2000"},{"key":"e_1_2_15_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.12-23.2002"},{"key":"e_1_2_15_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.739-745.2002"},{"key":"e_1_2_15_33_2","first-page":"26","article-title":"A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen","volume":"40","author":"Stone JA","year":"2002","journal-title":"Proc Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_2_15_34_2","first-page":"26","article-title":"Single dose caspofungin pharmacokinetics in healthy elderly subjects","volume":"40","author":"Stone JA","year":"2002","journal-title":"Proc Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_2_15_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.815-823.2004"},{"key":"e_1_2_15_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2339"},{"key":"e_1_2_15_37_2","first-page":"1274","article-title":"Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine","volume":"28","author":"Balani SK","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_15_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.596-600.2001"},{"key":"e_1_2_15_39_2","volume-title":"Caspofungin MSD: Summary of Product Characteristics","author":"MSD Sharp & Dohme Ltd","year":"2004"},{"key":"e_1_2_15_40_2","first-page":"1","article-title":"Effect of hepatic insufficiency on the pharmacokinetics of caspofungin","volume":"41","author":"Stone JA","year":"2002","journal-title":"Proc Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_2_15_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4306-4314.2004"},{"key":"e_1_2_15_42_2","first-page":"1","article-title":"Drug interactions between caspofungin and tacrolimus","volume":"41","author":"Stone JA","year":"2002","journal-title":"Proc Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_2_15_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704859"},{"key":"e_1_2_15_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2004.00065.x"},{"key":"e_1_2_15_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704516"},{"key":"e_1_2_15_46_2","first-page":"S33","article-title":"Efficacy of caspofungin in neutropenic and non\u2010neutropenic patients [Abstract]","volume":"31","author":"Glasmacher A","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_15_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.451-457.2002"},{"key":"e_1_2_15_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/323401"},{"key":"e_1_2_15_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01191-9"},{"key":"e_1_2_15_50_2","doi-asserted-by":"publisher","DOI":"10.1086\/318483"},{"key":"e_1_2_15_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0764-4"},{"issue":"2","key":"e_1_2_15_52_2","first-page":"S118","article-title":"Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients \u2013 guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"82","author":"Maschmeyer G","year":"2003","journal-title":"Ann Hematol"},{"key":"e_1_2_15_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/339215"},{"key":"e_1_2_15_54_2","first-page":"75","article-title":"Gu\u00eda cl\u00ednica para la evaluaci\u00f3n y el tratamiento del paciente neutrop\u00e9nico con fiebre","volume":"14","author":"Garcia Rodriguez JA","year":"2001","journal-title":"Rev Esp Quimioter"},{"key":"e_1_2_15_55_2","first-page":"630a","article-title":"Caspofungin therapy in documented fungal infections in patients with hematological disorders: Spanish experience before licensure of the drug","volume":"100","author":"Sanz\u2010Rodriguez C","year":"2002","journal-title":"Blood"},{"key":"e_1_2_15_56_2","volume-title":"Proc Intersci Conf Antimicrob Agents Chemother","author":"Morrissey CO","year":"2004"},{"key":"e_1_2_15_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2750"},{"key":"e_1_2_15_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2005.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2005.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:05:54Z","timestamp":1696885554000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2005.01131.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,27]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1439-0507.2005.01131.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2005.01131.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,27]]}}}